Immunotherapy (IO) and particularly immune checkpoint inhibitors (ICI), including programmed death receptor 1 (PD-1) and PD-ligand 1 (PD-L1) inhibitors have revolutionized the treatment landscape of non-small cell lung cancer (NSCLC). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.